ES1064414Y - Dispositivo para reducir la absorcion rapida de la dosis inducida por alcohol para formas de dosificacion oral de liberacion sostenida de opioides - Google Patents

Dispositivo para reducir la absorcion rapida de la dosis inducida por alcohol para formas de dosificacion oral de liberacion sostenida de opioides

Info

Publication number
ES1064414Y
ES1064414Y ES200602086U ES200602086U ES1064414Y ES 1064414 Y ES1064414 Y ES 1064414Y ES 200602086 U ES200602086 U ES 200602086U ES 200602086 U ES200602086 U ES 200602086U ES 1064414 Y ES1064414 Y ES 1064414Y
Authority
ES
Spain
Prior art keywords
dose
alcohol
dosage forms
sustained release
oral dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200602086U
Other languages
English (en)
Other versions
ES1064414U (es
Inventor
Gayatri Sathyan
Nipun Davar
Pors Linda H
Pujals Gemma Casadevall
Jayne Hastedt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37232345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES1064414(Y) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corp filed Critical Alza Corp
Publication of ES1064414U publication Critical patent/ES1064414U/es
Application granted granted Critical
Publication of ES1064414Y publication Critical patent/ES1064414Y/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
ES200602086U 2005-10-31 2006-09-22 Dispositivo para reducir la absorcion rapida de la dosis inducida por alcohol para formas de dosificacion oral de liberacion sostenida de opioides Expired - Fee Related ES1064414Y (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US73199505P 2005-10-31 2005-10-31
US60/731995 2005-10-31
US80201706P 2006-05-18 2006-05-18
US60/802017 2006-05-18
US83704906P 2006-08-11 2006-08-11
US60/837049 2006-08-11

Publications (2)

Publication Number Publication Date
ES1064414U ES1064414U (es) 2007-03-16
ES1064414Y true ES1064414Y (es) 2007-06-16

Family

ID=37232345

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200602086U Expired - Fee Related ES1064414Y (es) 2005-10-31 2006-09-22 Dispositivo para reducir la absorcion rapida de la dosis inducida por alcohol para formas de dosificacion oral de liberacion sostenida de opioides
ES06836771T Active ES2402666T3 (es) 2005-10-31 2006-10-31 Métodos de reducción de liberación masiva, inducida por el alcohol, en formas posológicas orales con liberación prolongada de opioides. Métodos de reducción de la liberación masiva, inducida por el alcohol, en formas posológicas orales con liberación prolongada de opioides

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES06836771T Active ES2402666T3 (es) 2005-10-31 2006-10-31 Métodos de reducción de liberación masiva, inducida por el alcohol, en formas posológicas orales con liberación prolongada de opioides. Métodos de reducción de la liberación masiva, inducida por el alcohol, en formas posológicas orales con liberación prolongada de opioides

Country Status (24)

Country Link
US (1) US20090221621A1 (es)
EP (1) EP1951232B1 (es)
JP (1) JP5315055B2 (es)
KR (1) KR101365031B1 (es)
CN (1) CN103800300A (es)
AT (1) AT10511U1 (es)
AU (1) AU2006308718C8 (es)
BE (1) BE1017786A3 (es)
BG (1) BG1145U1 (es)
CZ (1) CZ17801U1 (es)
DE (1) DE202006014131U1 (es)
DK (2) DK200600272U4 (es)
ES (2) ES1064414Y (es)
FI (1) FI7512U1 (es)
FR (1) FR2892634B3 (es)
HK (2) HK1106451A1 (es)
HU (1) HUP0600816A2 (es)
IE (1) IES20060793A2 (es)
NL (1) NL1032774C1 (es)
NO (2) NO20064997L (es)
PL (2) PL116330U1 (es)
PT (2) PT103597A (es)
SI (1) SI1951232T1 (es)
WO (1) WO2007053698A2 (es)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003004031A1 (en) 2001-07-06 2003-01-16 Endo Pharmaceuticals, Inc. Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
EP2957281A1 (en) 2001-09-21 2015-12-23 Egalet Ltd. Polymer release system
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
ES2360102T3 (es) 2003-03-26 2011-05-31 Egalet A/S Sistema para la liberación controlada de morfina.
DK2368553T3 (en) 2003-04-08 2015-02-09 Progenics Pharm Inc Pharmaceutical preparation comprising methylnaltrexone
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AU2006254554B2 (en) * 2005-06-03 2011-11-24 Egalet Ltd A solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102006051020A1 (de) * 2006-10-26 2008-04-30 Evonik Röhm Gmbh Verwendung von (Meth)acrylat-Copolymeren in Retard-Arzneiformen zur Verringerung des Einflusses von Ethanol auf die Wirkstofffreisetzung
EP2104493A2 (en) * 2007-01-16 2009-09-30 Egalet A/S Use of i) a polyglycol and n) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
CA2682129A1 (en) 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Crystal forms and uses thereof
ES2493590T3 (es) 2007-03-29 2014-09-12 Wyeth Llc Antagonistas de receptores opioides periféricos y usos de los mismos
WO2008121348A2 (en) 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
CA2923102C (en) * 2007-08-13 2019-10-15 Abuse Deterrent Pharmaceutical Llc Abuse resistant drugs, method of use and method of making
MX2010008138A (es) 2008-01-25 2010-08-10 Gruenenthal Gmbh Forma de dosis farmaceutica.
CA2713568C (en) 2008-02-06 2016-09-20 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
MX2010008861A (es) * 2008-02-15 2011-02-22 Sun Pharma Advanced Res Co Ltd Tableta oral de liberacion controlada con efecto de liberacion masiva reducido.
RU2508092C2 (ru) 2008-05-09 2014-02-27 Грюненталь Гмбх Способ получения твердой лекарственной формы, в частности таблетки для фармацевтического применения, и способ получения прекурсора твердой лекарственной формы, в частности таблетки
US20110250278A1 (en) 2008-07-01 2011-10-13 University Of Chicago Particles containing an opioid receptor antagonist and methods of use
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
ES2607209T3 (es) 2009-02-06 2017-03-29 Egalet Ltd. Composiciones farmacéuticas resistentes al abuso
EP2393484A1 (en) 2009-02-06 2011-12-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
US9730899B2 (en) 2009-03-18 2017-08-15 Evonik Roehm Gmbh Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising neutral vinyl polymers and excipients
AU2010265213B2 (en) 2009-06-24 2012-08-23 Egalet Ltd. Controlled release formulations
WO2011009604A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
AR077493A1 (es) 2009-07-22 2011-08-31 Gruenenthal Gmbh Composicion farmaceutica extruida en caliente con liberacion controlada. procedimiento de preparacion
EP2477614A2 (en) 2009-09-17 2012-07-25 Cadila Healthcare Limited Pharmaceutical compositions for reducing alcohol-induced dose dumping
EP2538926A2 (en) * 2010-02-24 2013-01-02 Pfizer Inc. Veterinary compositions
AU2011224350B2 (en) 2010-03-09 2015-07-02 Alkermes Pharma Ireland Limited Alcohol resistant enteric pharmaceutical compositions
MX2020011961A (es) 2010-03-24 2022-04-19 Jazz Pharmaceuticals Inc Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas.
AR082862A1 (es) 2010-09-02 2013-01-16 Gruenenthal Gmbh Forma de dosificacion resistente a alteracion que comprende un polimero anionico
WO2012028319A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
KR20140053159A (ko) 2011-07-29 2014-05-07 그뤼넨탈 게엠베하 즉시 약물 방출을 제공하는 탬퍼-저항성 정제
NO2736497T3 (es) 2011-07-29 2018-01-20
WO2013127831A1 (en) 2012-02-28 2013-09-06 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
WO2013158814A1 (en) 2012-04-18 2013-10-24 Mallinckrodt Llc Immediate release, abuse deterrent pharmaceutical compositions
PT2838512T (pt) 2012-04-18 2018-11-09 Gruenenthal Gmbh Forma farmacêutica resistente à adulteração e resistente à libertação inesperada de alta quantidade (dose-dumping)
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US9549899B2 (en) 2012-07-06 2017-01-24 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
KR102127625B1 (ko) 2012-09-03 2020-06-29 다이이찌 산쿄 가부시키가이샤 하이드로모르폰염산염 함유의 경구용 서방성 의약 조성물
EP2968182B8 (en) 2013-03-15 2018-07-25 SpecGx LLC Abuse deterrent solid dosage form for immediate release with functional score
AR096439A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido que contiene una o más partículas
BR112015026549A2 (pt) 2013-05-29 2017-07-25 Gruenenthal Gmbh forma de dosagem à prova de violação contendo uma ou mais partículas
KR20160031526A (ko) 2013-07-12 2016-03-22 그뤼넨탈 게엠베하 에틸렌-비닐 아세테이트 중합체를 함유하는 템퍼 내성 투여형
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
CN105934241B (zh) 2013-11-26 2020-06-05 格吕伦塔尔有限公司 通过低温研磨制备粉末状药物组合物
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EA201692388A1 (ru) 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
PL3164117T3 (pl) 2014-07-03 2024-03-11 SpecGx LLC Preparaty zapewniające natychmiastowe uwalnianie i powstrzymujące przed nadużywaniem, zawierające polisacharydy inne niż celuloza
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
EP3285745A1 (en) 2015-04-24 2018-02-28 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
US11103458B2 (en) * 2015-05-13 2021-08-31 4P-Pharma Stimulant abuse-deterrent compositions
CN107708677B (zh) * 2015-06-05 2021-07-13 赢创运营有限公司 耐乙醇影响的药物或保健品组合物
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US20190111001A1 (en) * 2016-03-30 2019-04-18 University Of Maryland, Baltimore Microparticulate system for colonic drug delivery
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
MX2021002459A (es) 2018-09-25 2021-04-29 SpecGx LLC Formas de dosificacion en capsula disuasorias del abuso de liberacion inmediata.
KR20210094513A (ko) 2018-11-19 2021-07-29 재즈 파마슈티칼즈 아일랜드 리미티드 알코올-내성 약물 제형
JP7263047B2 (ja) * 2019-02-25 2023-04-24 沢井製薬株式会社 フィルムコーティング錠剤
CA3127871A1 (en) 2019-03-01 2020-09-10 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2799241A (en) 1949-01-21 1957-07-16 Wisconsin Alumni Res Found Means for applying coatings to tablets or the like
US2707154A (en) * 1952-06-09 1955-04-26 Monsanto Chemicals Antioxidants and compositions containing same
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (es) 1960-11-29
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3546142A (en) 1967-01-19 1970-12-08 Amicon Corp Polyelectrolyte structures
CH508415A (de) 1967-10-27 1971-06-15 Hoffmann La Roche Antioxydative Mischung und deren Verwendung
US3573936A (en) 1967-12-15 1971-04-06 Rayonier Inc Plicatic acid and thiodipropionic acid as antioxidants for use in animal fats and vegetable oils
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) * 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3995631A (en) * 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US3865108A (en) * 1971-05-17 1975-02-11 Ortho Pharma Corp Expandable drug delivery device
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4002173A (en) 1974-07-23 1977-01-11 International Paper Company Diester crosslinked polyglucan hydrogels and reticulated sponges thereof
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4038434A (en) 1976-03-12 1977-07-26 Howard Hall & Company Antioxidant stabilized edible compositions
US4111201A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for delivering selected beneficial agents having varying degrees of solubility
US4111202A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4207893A (en) * 1977-08-29 1980-06-17 Alza Corporation Device using hydrophilic polymer for delivering drug to biological environment
US4186465A (en) * 1978-03-28 1980-02-05 Manning Jim L Safety lock
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4259323A (en) * 1980-03-24 1981-03-31 Hoffmann-La Roche Inc. Potassium chloride emulsion
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
IN159370B (es) * 1982-01-15 1987-05-09 Ciba Geigy Ag
US4681583A (en) 1982-12-20 1987-07-21 Alza Corporation System for dispersing drug in biological environment
US4578075A (en) 1982-12-20 1986-03-25 Alza Corporation Delivery system housing a plurality of delivery devices
US5082668A (en) 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4627850A (en) 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
US4663148A (en) 1984-03-21 1987-05-05 Alza Corporation Dispenser comprising telescopically engaging members
US4681853A (en) * 1985-10-23 1987-07-21 Hardy Kenneth J Perfusion slit chamber for filter-bound sample analyses
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US4915949A (en) * 1987-07-13 1990-04-10 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
US5019397A (en) 1988-04-21 1991-05-28 Alza Corporation Aqueous emulsion for pharmaceutical dosage form
US5024842A (en) * 1988-04-28 1991-06-18 Alza Corporation Annealed coats
US5006346A (en) * 1988-04-28 1991-04-09 Alza Corporation Delivery system
US5160743A (en) * 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
US4931285A (en) * 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
CA1340821C (en) * 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
US5126142A (en) * 1989-07-18 1992-06-30 Alza Corporation Dispenser comprising ionophore
US5091190A (en) 1989-09-05 1992-02-25 Alza Corporation Delivery system for administration blood-glucose lowering drug
US5324280A (en) * 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
US5252338A (en) * 1991-06-27 1993-10-12 Alza Corporation Therapy delayed
US5190765A (en) 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
EP0669128B1 (en) * 1992-11-17 2000-01-05 Yoshitomi Pharmaceutical Industries, Ltd. Sustained-release microsphere containing antipsychotic and process for producing the same
US5643909A (en) 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
EP0647448A1 (en) * 1993-10-07 1995-04-12 Euroceltique S.A. Orally administrable opioid formulations having extended duration of effect
US5650173A (en) 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
ATE288270T1 (de) 1993-11-19 2005-02-15 Janssen Pharmaceutica Nv Mikroverkapselte 1,2-benzazole
DK0729353T4 (da) 1993-11-19 2012-10-01 Alkermes Inc Fremstilling af bionedbrydelige mikropartikler som indeholder et biologisk aktivt middel
ZA953078B (en) 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5529787A (en) * 1994-07-07 1996-06-25 Alza Corporation Hydromorphone therapy
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
US5614578A (en) 1994-10-28 1997-03-25 Alza Corporation Injection-molded dosage form
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5534263A (en) 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
US5824638A (en) * 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
WO1998006380A2 (en) 1996-08-16 1998-02-19 Alza Corporation Dosage form for providing ascending dose of drug
ES2264173T3 (es) 1996-11-25 2006-12-16 Alza Corporation Forma de dosificacion para suministrar una dosis creciente.
AU8293498A (en) * 1997-07-02 1999-01-25 Euro-Celtique S.A. Stabilized sustained release tramadol formulations
UA53774C2 (uk) * 1997-12-22 2003-02-17 Еро-Селтік, С.А. Спосіб запобігання зловживанню лікарськими формами, що містять опіоїди
PT1083879E (pt) 1998-06-03 2005-01-31 Alza Corp Metodos e dispositivos para proporcionar uma terapia de drogas prolongada
US6551613B1 (en) * 1998-09-08 2003-04-22 Alza Corporation Dosage form comprising therapeutic formulation
US6174547B1 (en) 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
HUP0104721A3 (en) * 1998-12-17 2006-07-28 Alza Corp Mountain View Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US20030118641A1 (en) 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
EP1499291B1 (en) * 2002-04-29 2009-01-07 ALZA Corporation Methods and dosage forms for controlled delivery of oxycodone

Also Published As

Publication number Publication date
AU2006308718B2 (en) 2013-01-10
HU0600816D0 (en) 2006-12-28
AU2006308718C1 (en) 2015-10-08
WO2007053698A3 (en) 2007-06-28
FR2892634A3 (fr) 2007-05-04
DK1951232T3 (da) 2013-05-06
DK200600272U1 (da) 2007-02-23
AT10511U1 (de) 2009-05-15
PT103597A (pt) 2007-05-31
HUP0600816A2 (en) 2008-05-28
NO20082460L (no) 2008-07-30
BG1145U1 (bg) 2009-02-27
HK1106451A1 (en) 2008-03-14
AU2006308718A1 (en) 2007-05-10
ES2402666T3 (es) 2013-05-07
NL1032774C1 (nl) 2007-05-02
KR101365031B1 (ko) 2014-02-21
CN103800300A (zh) 2014-05-21
PT1951232E (pt) 2013-05-13
IES20060793A2 (en) 2007-05-30
AU2006308718C8 (en) 2015-12-24
FR2892634B3 (fr) 2007-09-14
SI1951232T1 (sl) 2013-06-28
NO20064997L (no) 2007-05-02
FI7512U1 (fi) 2007-05-25
US20090221621A1 (en) 2009-09-03
ES1064414U (es) 2007-03-16
KR20080064198A (ko) 2008-07-08
BE1017786A3 (de) 2009-07-07
JP5315055B2 (ja) 2013-10-16
HK1115070A1 (en) 2008-11-21
PL1951232T3 (pl) 2013-09-30
EP1951232A4 (en) 2009-03-11
EP1951232A2 (en) 2008-08-06
JP2009513717A (ja) 2009-04-02
DK200600272U4 (da) 2008-06-13
WO2007053698A2 (en) 2007-05-10
CZ17801U1 (cs) 2007-09-03
PL116330U1 (en) 2007-04-02
DE202006014131U1 (de) 2007-01-04
FIU20060451U0 (fi) 2006-10-30
EP1951232B1 (en) 2013-04-03

Similar Documents

Publication Publication Date Title
ES1064414Y (es) Dispositivo para reducir la absorcion rapida de la dosis inducida por alcohol para formas de dosificacion oral de liberacion sostenida de opioides
IL190618A0 (en) Solid orally administerable pharmaceutical dosage forms with rapid active principle release
ATE458486T1 (de) Feste, oral applizierbare pharmazeutische darreichungsformen enthaltend rivaroxaban mit modifizierter freisetzung
DK2080514T3 (da) Manipulationssikre orale farmaceutiske doseringsformer omfattende et opioidanalgetikum
ATE532788T1 (de) Pharmazeutische verbindungen
DE602006012895D1 (de) Not-Aus-Vorrichtung
BRPI0616703A2 (pt) forma de dosagem farmacêutica
ITBO20050123A1 (it) Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
DK3424932T3 (da) Bronophthalider til terapeutisk anvendelse
BRPI0817200A2 (pt) composições oftálmicas sólida e uso de compostos para fabricação de medicamento
HN2004000490A (es) Procedimiento para la preparacion de una composicion farmaceutica solida administrable oralmente
CL2013001885A1 (es) Compuestos derivados de morfina, antagonistas del receptor ipiode periferico; composicion farmaceutica; formulacion oral; y uso para reducir los efectos colaterales de la terapia opioide (div. sol. 905-08).
BRPI0820673A2 (pt) Formulações e composições farmacêuticas de fenilefrina para absorção transmucosal
BRPI0919231A2 (pt) agonista de receptor de neuropeptídeo-2, composição farmacêutica que o compreende, seu uso e método para o tratamento ou profilaxia de enfermidades
SI1915153T1 (sl) Terapevtski sistemi s takojšnjim sproščanjem za izboljšano oralno absorpcijo 7-((E)-terc.-butiloksiiminometil)kamptotecina
CL2007003198A1 (es) Compuestos diarilicos opcionalmente nitrogenados, antagonistas de los receptores opioides; composicion farmaceutica; y uso en el tratamiento de la obesidad.
BRPI0815019A2 (pt) Dispositivo e emprego para o armazenamento e a preparação de wafers de medicamento
BRPI0720684A2 (pt) composto, medicamento, composição farmacêutica que contém e uso do composto
CL2007003395A1 (es) Uso de agomelatina para la obtencion de medicamentos destinados al tratamiento de leucomalacia periventricular.
ITMI20051953A1 (it) Dispositivo inalatotre portatile per la somministrazione di aromi e-o medicinali
ITMI20050278A1 (it) Procedimento per la preparazione del toremifene
FI20050212A0 (fi) Modifioidusti vapauttava annosmuoto
HK1103517A1 (en) Pharmaceutical composition comprising memantine in an extended dosage release form for use in the treatment of dementias
ES1060670Y (es) Cama para estabulacion de ganado vacuno

Legal Events

Date Code Title Description
FG1K Utility model granted
FD1K Utility model lapsed

Effective date: 20161230